Efficacy And Safety Of Chiglitazar, A Novel Peroxisome Proliferator- Activated Receptor Pan-Agonist, In Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial (Cmap)
SCIENCE BULLETIN（2021）
摘要
Type 2 diabetes Glycemic control Insulin resistance
更多查看译文
关键词
Chiglitazar, Carfloglitazar, PPAR pan-agonist, Type 2 diabetes, Glycemic control, Insulin resistance
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要